The company trades a wide variety of pharmaceutical raw materials, including advanced intermediates and active ingredients, acting as a middleman between chemical manufacturers and drug producers.
The company operates as a pure trading entity with razor-thin net margins (0.69%) and no proprietary technology or brand power. The massive revenue spike followed by an 89% collapse suggests a lack of stable customer relationships or competitive differentiation.
Capital has been primarily used to fund working capital and a 100% owned Singapore subsidiary. The company frequently alters its capital structure through bonus issues and stock splits rather than generating sustainable cash flow for reinvestment.
The business collapsed as the 89% revenue decline proved to be a permanent loss of trading volume rather than a temporary dip. Governance failures, evidenced by the inability to maintain a legal board and the GST department's pursuit of massive tax credit discrepancies, led to a liquidity crisis. With negative cash conversion and razor-thin margins, the company lacked the internal resources to survive regulatory penalties or the loss of its primary trading partners, eventually resulting in a total breakdown of the trading model and a wipeout of equity value.
RichFakir rates Remedium Lifecare Ltd's business quality as poor — 19/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Remedium Lifecare Ltd is trading about 46% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Remedium Lifecare Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Remedium Lifecare Ltd's fair value is about ₹0 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →